Madrigal Pharmaceuticals IncNASDAQ:MDGL
- LAST PRICE248.6800
- TODAY'S CHANGE (%)-7.4900 (-2.9238%)
- Bid / Lots245.0000/ 1
- Ask / Lots262.0000/ 1
- Open / Previous Close256.8500 / 256.1700
- Day Range
- 52 Week Range
- Volume167,957
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDGL |
|---|---|---|
| 09:32 ET | 1307 | 256.85 |
| 09:39 ET | 150 | 255.48 |
| 09:45 ET | 100 | 255.785 |
| 09:48 ET | 200 | 254.95 |
| 09:52 ET | 100 | 254.12 |
| 09:56 ET | 750 | 253.95 |
| 09:57 ET | 112 | 253.66 |
| 10:14 ET | 100 | 253.5 |
| 10:17 ET | 755 | 253.5 |
| 10:19 ET | 100 | 252.81 |
| 10:21 ET | 600 | 253.4 |
| 10:30 ET | 100 | 252.72 |
| 10:37 ET | 200 | 253.78 |
| 10:46 ET | 148 | 253.77 |
| 10:50 ET | 100 | 253.24 |
| 11:04 ET | 100 | 253.755 |
| 11:08 ET | 100 | 253.665 |
| 11:09 ET | 599 | 253.215 |
| 11:15 ET | 100 | 253.98 |
| 11:38 ET | 100 | 252.975 |
| 11:42 ET | 400 | 252 |
| 11:44 ET | 294 | 252.495 |
| 11:47 ET | 1600 | 250.5 |
| 11:49 ET | 824 | 250 |
| 11:54 ET | 300 | 250.11 |
| 11:58 ET | 150 | 250.105 |
| 12:00 ET | 406 | 250.1 |
| 12:02 ET | 683 | 250.21 |
| 12:03 ET | 800 | 250.2 |
| 12:05 ET | 1821 | 250.405 |
| 12:07 ET | 700 | 250.5 |
| 12:09 ET | 500 | 250.73 |
| 12:12 ET | 1000 | 250.635 |
| 12:14 ET | 600 | 250.64 |
| 12:16 ET | 100 | 250.905 |
| 12:18 ET | 132 | 250.635 |
| 12:21 ET | 225 | 250.31 |
| 12:23 ET | 500 | 251.25 |
| 12:25 ET | 2372 | 251.49 |
| 12:30 ET | 100 | 252 |
| 12:34 ET | 220 | 251.895 |
| 12:38 ET | 100 | 251.56 |
| 12:39 ET | 100 | 251.56 |
| 12:41 ET | 100 | 251.705 |
| 12:48 ET | 461 | 250.87 |
| 12:50 ET | 600 | 250.44 |
| 12:52 ET | 200 | 250.72 |
| 12:54 ET | 670 | 249.94 |
| 12:59 ET | 100 | 249.53 |
| 01:01 ET | 800 | 249.13 |
| 01:03 ET | 200 | 249.35 |
| 01:06 ET | 100 | 249.05 |
| 01:08 ET | 100 | 249.185 |
| 01:10 ET | 300 | 249.54 |
| 01:12 ET | 100 | 250.01 |
| 01:14 ET | 100 | 250.09 |
| 01:19 ET | 100 | 250.69 |
| 01:24 ET | 100 | 250.7377 |
| 01:28 ET | 200 | 250.83 |
| 01:32 ET | 100 | 250.785 |
| 01:33 ET | 100 | 250.14 |
| 01:39 ET | 200 | 250.12 |
| 01:44 ET | 100 | 249.91 |
| 01:46 ET | 100 | 250.01 |
| 01:51 ET | 800 | 249.67 |
| 01:53 ET | 1100 | 249.93 |
| 01:55 ET | 256 | 249.505 |
| 01:57 ET | 300 | 248.82 |
| 02:00 ET | 200 | 248.96 |
| 02:02 ET | 300 | 248.6 |
| 02:04 ET | 700 | 249.32 |
| 02:26 ET | 600 | 248.89 |
| 02:29 ET | 200 | 249.28 |
| 02:36 ET | 100 | 250.12 |
| 02:38 ET | 100 | 251.19 |
| 02:47 ET | 600 | 250.57 |
| 02:56 ET | 1605 | 250.72 |
| 03:00 ET | 100 | 250.43 |
| 03:02 ET | 100 | 250.21 |
| 03:03 ET | 100 | 250.06 |
| 03:05 ET | 100 | 250.13 |
| 03:07 ET | 6608 | 250.29 |
| 03:09 ET | 800 | 250.58 |
| 03:12 ET | 863 | 250.445 |
| 03:14 ET | 700 | 251.1071 |
| 03:18 ET | 1000 | 251.48 |
| 03:23 ET | 300 | 251.5 |
| 03:25 ET | 300 | 251.515 |
| 03:27 ET | 200 | 251.16 |
| 03:32 ET | 300 | 250.535 |
| 03:34 ET | 100 | 250.54 |
| 03:36 ET | 570 | 250.32 |
| 03:38 ET | 600 | 250.02 |
| 03:39 ET | 559 | 250.02 |
| 03:41 ET | 8937 | 248.38 |
| 03:43 ET | 446 | 247.965 |
| 03:45 ET | 402 | 248.36 |
| 03:48 ET | 100 | 247.59 |
| 03:50 ET | 1600 | 248.16 |
| 03:52 ET | 2954 | 248.49 |
| 03:54 ET | 300 | 248.3 |
| 03:56 ET | 3699 | 247.82 |
| 03:57 ET | 1000 | 248.32 |
| 03:59 ET | 27977 | 248.68 |
Aug 8, 2024
DJ Madrigal Pharmaceuticals Is Maintained at Buy by Citigroup, from 3:32PM ET on Thursday Aug 08, 2024 by Dow Jones
3:32PM ET on Thursday Aug 08, 2024 by Dow JonesDJ Madrigal Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group, from 9:19AM ET on Thursday Aug 08, 2024 by Dow Jones
9:19AM ET on Thursday Aug 08, 2024 by Dow Jones
Aug 7, 2024
*DJ Madrigal Pharmaceuticals 2Q Loss/Shr $7.10 >MDGL, from 7:00AM ET on Wednesday Aug 07, 2024 by Dow Jones
7:00AM ET on Wednesday Aug 07, 2024 by Dow JonesMadrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates, from 7:00AM ET on Wednesday Aug 07, 2024 by Dow Jones
7:00AM ET on Wednesday Aug 07, 2024 by Dow Jones
Aug 2, 2024
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel, from 7:00AM ET on Friday Aug 02, 2024 by Dow Jones
7:00AM ET on Friday Aug 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Madrigal Pharmaceuticals Inc | 5.6B | -9.8x | --- |
Nuvalent Inc | 5.4B | -29.8x | --- |
Avidity Biosciences Inc | 5.2B | -14.5x | --- |
Krystal Biotech Inc | 5.8B | 54.1x | --- |
Immunovant Inc | 4.8B | -16.4x | --- |
BridgeBio Pharma Inc | 4.8B | -9.4x | --- |
Company Information
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Contact Information
- Headquarters
- 200 Barr Harbor Dr Ste 400WEST CONSHOHOCKEN, PA, United States 19428-2978
- Phone
- 404-380-9263
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Julian Baker
- President, Chief Executive Officer, Director
- Bill Sibold
- Chief Financial Officer, Senior Vice President
- Mardi Dier
- President of Research and Development, Chief Medical Officer, Director
- Rebecca Taub
- General Counsel
- Shannon Kelley
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.6B |
|---|---|
Revenue (TTM) | $14.6M |
Shares Outstanding | 21.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.43 |
EPS | $-25.50 |
Book Value | $20.39 |
P/E Ratio | -9.8x |
Price/Sales (TTM) | 380.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,622.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
